Nuvalent, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in patients with cancer. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company leverages expertise in chemistry and structure-based drug design to develop small-molecule inhibitors that overcome resistance, minimize adverse events, address brain metastases, and drive durable responses; its operations are primarily conducted in the United States, targeting oncology patients with non-small cell lung cancer (NSCLC) and other solid tumors. Nuvalent advances a robust pipeline featuring lead candidates zidesamtinib (NVL-520), a novel brain-penetrant ROS1-selective inhibitor in Phase 2 of the ARROS-1 trial for TKI-pretreated and naive advanced ROS1-positive NSCLC and other solid tumors; neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor in Phase 2 of the ALKOVE-1 trial for advanced ALK-positive NSCLC and other solid tumors, with the ALKAZAR Phase 3 trial initiated in July 2025 for TKI-naive ALK-positive NSCLC; and NVL-330, a brain-penetrant HER2-selective inhibitor in Phase 1 of the HEROEX-1 trial for HER2-altered NSCLC, alongside multiple discovery-stage programs. Recent milestones include the completion of a rolling New Drug Application (NDA) submission for zidesamtinib in TKI-pretreated advanced ROS1-positive NSCLC patients in Q3 2025, with FDA acceptance under the Real-Time Oncology Review pilot program and presentation of supporting pivotal data from the ARROS-1 trial at the IASLC 2025 World Conference on Lung Cancer; positive pivotal data readout for zidesamtinib in June 2025 aligning with FDA on NDA strategy; initiation of the ALKAZAR Phase 3 trial for neladalkib in July 2025; FDA Breakthrough Therapy Designation for neladalkib received earlier in 2025; appointment of Christy Oliger to the board in June 2025; and publication in Molecular Cancer Therapeutics reinforcing zidesamtinib's design rationale in April 2025, alongside ongoing enrollment and preclinical data presentations at major conferences including AACR and ASCO.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
Here Are Wednesday’s Top Wall Street Analyst Research Calls: BILL Holdings, Cava Group, Entergy, GlobalFoundries, Hess Midstream, Nike, Pfizer, SharkNinja, STMicroelectronics, and More
Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline